跳至主要内容
临床试验/NCT01294241
NCT01294241已完成2 期

Open, Prospective, Controlled Case Series Documentation to Compare Intra-individually the Efficacy and Tolerance of Sericare® Versus Non-adhesive Wound Dressing Alone in Accelerating the Epithelialization of Skin Lesions of Patients With Epidermolysis Bullosa Hereditaria

Birken AG1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2010年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
10
试验地点
1
主要终点
Intra-individual Difference in Reepithelialization of Wound (Halves) at Day 14 in 'Recent Wounds' or Day 28 in 'Chronic Wounds'

研究概览

简要总结

The purpose of this study was to compare intra-individually the reepithelialization of skin lesion(s) in inherited Epidermolysis bullosa (either 1 wound ≥10 cm2 and ≤200 cm2 in size divided in 2 equal halves or 2 comparable wounds of ≥5 cm2 each) treated with Oleogel-S10 and non-adhesive wound dressing versus non-adhesive wound dressing only.

详细描述

This study was designed as an open-label, prospective, controlled, blindly evaluated, monocentric phase II case series documentation in patients with inherited Epidermolysis bullosa (EB). The investigator either identified 1 EB wound ≥10 cm2 and ≤200 cm2 in size and divided it into 2 halves or selected 2 comparable wounds of ≥5 cm2 each. One (half of the) EB wound was treated with Oleogel-S10 and non-adhesive wound dressing. The other wound (half) was covered with a non-adhesive wound dressing only (Mepilex®) as control. Wound dressings were changed about every 24 to 48 hours until discharge from hospital or until the end of treatment at Day 14 in 'recent wounds' or Day 28 in 'chronic wounds'. This was an open-label study. The investigator, the participant, and the sponsor knew the identity of the treatment. Two independent experts were blind to treatment and assessed efficacy based on chronological series of cropped and coded photographs by wound (half) that were taken before start of treatment, during wound dressing changes and at the end of treatment on Day 14/Day 28.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
Single (Outcomes Assessor)

盲法说明

Blinded comparison of wound photo series by two independent experts

入排标准

年龄范围
1 Year 至 95 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients aged 1-95 years
  • Patient and/or his/her legal representative was informed, read and understood the patient information/informed consent form and gave written informed consent
  • Patients with inherited EB with at least 1 skin lesion between 10 cm2 and 200 cm2 (alternatively 2 comparable lesions of at least 5 cm2 each)
  • Patient and/or his/her legal representative was able and willing to follow study procedures and instructions including the following:
  • Application of Oleogel-S10 on (1 half of) the wound at every wound dressing change
  • Regular visits during the treatment period (14 days in 'recent wounds' to 28 days in 'chronic wounds')
  • Negative pregnancy test in women of childbearing potential within 7 days before start of treatment
  • Women of childbearing potential agreed to use an effective method of contraception (Pearl Index < 1, e.g. hormonal contraception including the combined oral contraceptive pill, the transdermal patch, and the contraceptive vaginal ring, intrauterine devices or sterilization) during treatment and for at least 6 months thereafter
  • Men of procreative capacity agreed to use an effective method of contraception during treatment and for at least 6 months thereafter

排除标准

  • Systemic treatment with steroids during the last 30 days
  • Uncontrolled diabetes mellitus or diabetic ulcers
  • Diseases or conditions that could, in the opinion of the investigator, interfere with the assessment of safety, tolerance or efficacy
  • Skin disorders adversely affecting wound healing or involving the areas eligible for study treatment
  • Hypersensitivity to the trial medication or surgical dressings to be used
  • Multiple allergic disorders
  • Administration of investigational drugs within 3 months before screening
  • Investigations or changes in management for an existing medical condition
  • Low probability to complete the study per protocol for whatever reason

研究组 & 干预措施

Oleogel-S10

Experimental

The eligible wound (half) was topically treated with Oleogel-S10 and covered with a non-adhesive wound dressing (Mepilex®) on Day 0. Wound dressings were changed about every 24 to 48 hours until discharge from hospital or until the end of treatment at Day 14 in 'recent wounds' or Day 28 in 'chronic wounds'.

干预措施: Oleogel-S10 (Drug)

Oleogel-S10

Experimental

The eligible wound (half) was topically treated with Oleogel-S10 and covered with a non-adhesive wound dressing (Mepilex®) on Day 0. Wound dressings were changed about every 24 to 48 hours until discharge from hospital or until the end of treatment at Day 14 in 'recent wounds' or Day 28 in 'chronic wounds'.

干预措施: Mepilex® soft silicone faced polyurethane foam dressing (Device)

Non-adhesive wound dressing

Other

Mepilex® soft silicone faced polyurethane foam dressing was used as non-active comparator. The eligible wound (half) was covered with Mepilex® as control on Day 0. Wound dressings were changed about every 24 to 48 hours until discharge from hospital or until the end of treatment at Day 14 in 'recent wounds' or Day 28 in 'chronic wounds'.

干预措施: Mepilex® soft silicone faced polyurethane foam dressing (Device)

结局指标

主要结局

Intra-individual Difference in Reepithelialization of Wound (Halves) at Day 14 in 'Recent Wounds' or Day 28 in 'Chronic Wounds'

时间窗: 14 days for 'recent wounds', 28 days for 'chronic wounds'

The primary end point was the progress of reepithelialization from baseline to either Day 14 ('recent wounds') or Day 28 ('chronic wounds') of the EB wound (half) treated with Oleogel-S10 and non-adhesive wound dressing (Mepilex®) intra-individually compared to the other wound (half) covered with non-adhesive wound dressing only (intra-individual comparison). Two independent experts were blind to treatment and assessed efficacy based on chronological series of cropped and coded photographs by wound (half) that were taken before start of treatment, during wound dressing changes and at the end of treatment on Day 14/Day 28. They evaluated each series and decided whether 1 wound (half) reepithelialized faster than the other ('winner'), or whether there was no difference in reepithelialization.

次要结局

  • Percentage of Wound Epithelialization at Day 7±1(Day 7±1)
  • Percentage of Wound Epithelialization at Day 14±1(Day 14±1)

研究者

发起方
Birken AG
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验